Intellia Therapeutics (NTLA) News Today $9.60 +0.03 (+0.26%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Wedbush Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)June 18 at 6:38 AM | theglobeandmail.comIntellia Therapeutics (NASDAQ:NTLA) Earns Neutral Rating from WedbushJune 18 at 2:23 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Intellia Therapeutics (NASDAQ:NTLA)June 18 at 1:23 AM | americanbankingnews.comIntellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside PotentialJune 17 at 3:36 PM | msn.comIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Here's WhyIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Here's What HappenedJune 17 at 12:16 PM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Receives Neutral Rating from WedbushWedbush reissued a "neutral" rating and issued a $7.00 price target on shares of Intellia Therapeutics in a report on Monday.June 16 at 1:46 PM | marketbeat.com6NTLA : Assessing Intellia Therapeutics: Insights From 9 Financial...June 16 at 8:44 AM | benzinga.comIntellia Therapeutics' (NTLA) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Intellia Therapeutics in a report on Monday.June 16 at 8:17 AM | marketbeat.comIntellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology CongressJune 15 at 10:45 AM | globenewswire.comCantor Fitzgerald Estimates NTLA FY2026 EarningsJune 11, 2025 | americanbankingnews.comBrokers Issue Forecasts for NTLA FY2026 EarningsIntellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Intellia Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski expects that the company will post eJune 10, 2025 | marketbeat.comIntellia Therapeutics Inc.June 9, 2025 | barrons.comIntellia Therapeutics (NASDAQ:NTLA) Trading Up 8.7% - Should You Buy?Intellia Therapeutics (NASDAQ:NTLA) Trading 8.7% Higher - Still a Buy?June 6, 2025 | marketbeat.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Wellington Management Group LLPWellington Management Group LLP lifted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 8.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 699,814 shares of the company'June 4, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-one analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendJune 4, 2025 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock PriceCanaccord Genuity Group decreased their price target on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a research report on Tuesday.June 3, 2025 | marketbeat.comNuveen Asset Management LLC Decreases Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Nuveen Asset Management LLC cut its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 28.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 260,697 shares of the company's stock after selling 105June 3, 2025 | marketbeat.comEvercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)June 1, 2025 | theglobeandmail.comSquarepoint Ops LLC Has $1.18 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Squarepoint Ops LLC increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 58.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 101,417 shares of the company's stock afterJune 1, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 5.6% - Here's What HappenedIntellia Therapeutics (NASDAQ:NTLA) Shares Down 5.6% - Time to Sell?May 31, 2025 | marketbeat.comSA analyst downgrades: PLTR, PSTG, NTLA, ARWRMay 30, 2025 | msn.comIntellia Therapeutics (NASDAQ:NTLA) Shares Up 4.7% - Here's What HappenedIntellia Therapeutics (NASDAQ:NTLA) Trading 4.7% Higher - Here's What HappenedMay 30, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Down - What's Next?Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Down - Time to Sell?May 30, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a report on Thursday.May 30, 2025 | marketbeat.comIntellia: Heart Disease Safety Setback Triggers Selloff - Caution AdvisedMay 29, 2025 | seekingalpha.comIntellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The DipMay 29, 2025 | msn.comIntellia Shares Drop 19% After Safety Signal Emerges in Phase 3 TrialMay 29, 2025 | msn.comDemystifying Intellia Therapeutics: Insights From 9 Analyst ReviewsMay 29, 2025 | benzinga.comIntellia stock tumbles on safety concernsMay 29, 2025 | finance.yahoo.comIntellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On CourseMay 29, 2025 | benzinga.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. boosted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1,144.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 282,400 shares of the compMay 28, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Millennium Management LLCMillennium Management LLC raised its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 190.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 668,926 shares of the companyMay 28, 2025 | marketbeat.comBank of America Corp DE Trims Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Bank of America Corp DE cut its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 10.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 639,696 shares of the company's stock after selling 76,495 shares dMay 27, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Trading Down 4.3% - Time to Sell?Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 4.3% - Time to Sell?May 25, 2025 | marketbeat.comVoloridge Investment Management LLC Acquires 1,059,751 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Voloridge Investment Management LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 226.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,526,994 shares of the company's stock after buying an additional 1,059,751 shares durMay 25, 2025 | marketbeat.comTwo Sigma Investments LP Has $21.50 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Two Sigma Investments LP raised its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 88.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,843,743 shares of the company's stock after purcMay 24, 2025 | marketbeat.comDeutsche Bank AG Raises Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Deutsche Bank AG boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 12.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 252,501 shares of the company's stock after purchasing an additional 27,282 shares duringMay 24, 2025 | marketbeat.comAnalysts Think These Stocks Could More Than Double in Value (NTLA)Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.May 23, 2025 | marketbeat.comTwo Sigma Advisers LP Acquires 970,700 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Two Sigma Advisers LP boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 94.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,998,317 shares of the company's stock after buying an aMay 23, 2025 | marketbeat.comINTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMay 22, 2025 | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research note on Tuesday.May 22, 2025 | marketbeat.comVestal Point Capital LP Makes New $6.12 Million Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Vestal Point Capital LP acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 525,000 shares of the company's stMay 21, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Tema Etfs LLC purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 148,167 shares of the company's stock, valued at approximately $1,May 20, 2025 | marketbeat.comSecond Line Capital LLC Takes Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Second Line Capital LLC purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 131,122 shares of the coMay 19, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Northern Trust CorpNorthern Trust Corp grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 13.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 979,137 shares of the company's stock after acquiring an additional 112,847 shares during the qMay 19, 2025 | marketbeat.comIntellia Therapeutics announces two-year follow-up data from trial of nex-zMay 18, 2025 | msn.comIntellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual MeetingMay 18, 2025 | globenewswire.comSphera Funds Management LTD. Grows Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Sphera Funds Management LTD. grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 60.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 466,080 shares of thMay 18, 2025 | marketbeat.comPolar Asset Management Partners Inc. Boosts Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Polar Asset Management Partners Inc. boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1,144.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 282,400 shares of the company'sMay 18, 2025 | marketbeat.com Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.350.56▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼1212▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACADIA Pharmaceuticals News Merus News Avidity Biosciences News SpringWorks Therapeutics News Arcellx News Ultragenyx Pharmaceutical News Protagonist Therapeutics News Scholar Rock News Kymera Therapeutics News Viking Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredElon’s End Game Is Going Live -- And It Could Make You a FortuneThe media and the so-called experts have laughed at Elon Musk his entire career. CBS called PayPal “one of ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredThe Dollar Reset Nobody’s Talking AboutCould this man take down the financial system? In March, the Senate granted sweeping powers to a Harvard ec...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NTLA Stock Free NTLA Stock Alerts